Company Arecor Therapeutics plc

Equities

AREC

GB00BMWLM973

Biotechnology & Medical Research

Delayed London S.E. 09:40:51 14/06/2024 BST 5-day change 1st Jan Change
125.1 GBX -1.88% Intraday chart for Arecor Therapeutics plc -21.32% -31.45%

Business Summary

Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.

Number of employees: 51

Sales per Business

GBP in Million2022Weight2023Weight Delta
Biotechnology
100.0 %
2 100.0 % 5 100.0 % +90.30%

Sales per region

GBP in Million2022Weight2023Weight Delta
United Kingdom
63.3 %
1 47.3 % 3 63.3 % +154.67%
United States
12.2 %
1 32.6 % 1 12.2 % -29.08%
Switzerland
10.7 %
0 10.0 % 0 10.7 % +103.33%
Germany
7.3 %
-- 0 7.3 % -
Italy
6.0 %
-- 0 6.0 % -
India
0.7 %
0 5.6 % 0 0.7 % -77.78%

Managers

Managers TitleAgeSince
Chief Executive Officer 49 31/12/14
Director of Finance/CFO 65 31/12/18
Chief Tech/Sci/R&D Officer - 31/07/07
Corporate Officer/Principal - -
General Counsel - -
Corporate Officer/Principal - 04/04/23

Members of the board

Members of the board TitleAgeSince
Director/Board Member 78 12/04/21
Director/Board Member 66 30/04/21
Chairman 64 12/04/21
Director of Finance/CFO 65 31/12/18
Chief Executive Officer 49 31/12/14
Director/Board Member 59 31/08/17
Director/Board Member 61 -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 30,626,986 14,860,334 ( 48.52 %) 0 48.52 %

Shareholders

NameEquities%Valuation
Chelverton Asset Management Ltd.
4.653 %
1,425,000 4.653 % 3 M p
Unicorn Asset Management Ltd.
3.914 %
1,198,828 3.914 % 2 M p
867,738 2.833 % 2 M p
Amati Global Investors Ltd. (Venture Capital)
2.740 %
839,155 2.740 % 2 M p
Canaccord Genuity Wealth Ltd.
2.063 %
631,687 2.063 % 1 M p
CRUX Asset Management Ltd.
1.812 %
554,897 1.812 % 1 M p
Calculus Capital Ltd.
1.402 %
429,474 1.402 % 869 423 p
Jan Jezek
1.332 %
407,808 1.332 % 825 562 p
201,849 0.6591 % 408 621 p
154,626 0.5049 % 313 023 p

Company contact information

Arecor Therapeutics Plc

Chesterford Research Park

CB10 1XL, Little Chesterford

+44 1223 426 060

http://www.arecor.com
address Arecor Therapeutics plc(AREC)
  1. Stock Market
  2. Equities
  3. AREC Stock
  4. Company Arecor Therapeutics plc
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW